Inhibikase Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Inhibikase Therapeutics, Inc. (IKT) had Debt Securities, Available-for-sale, Amortized Cost of $127.88 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $127.88M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $120.82M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $39.52M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $39.06M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $127.88M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $120.82M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $39.52M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $39.06M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $9.93M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $19.74M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $41.09M 10-K · filed 2026-03-26 |
| 2024-09-30 | $2.33M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $4.85M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $7.40M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $4.09M 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.97M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $19.03M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $21.60M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $15.76M 10-K · filed 2024-03-27 |
| 2022-09-30 | $20.73M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |